Press Releases

12/10/14 4:45 pm EST
Tenax Therapeutics to Provide Corporate Update and Discuss Second Quarter Fiscal Year 2015 Financial Results on December 17, 2014
11/25/14 7:00 am EST
Small Cap IR Issues Tenax Therapeutics Analyst Report: Large Validated Market Opportunity Inspires $12 Price Target
10/31/14 7:00 am EDT
Tenax Therapeutics Analyst Brief: Emerging Biopharmaceutical Player Back In the Clinical Trial Business -- Technical Exhaustion Setup Playing Out by Small Cap Traders
09/24/14 8:00 am EDT
Tenax Therapeutics Announces First Quarter Fiscal Year 2015 Financial Results
09/22/14 8:30 am EDT
Tenax Therapeutics Announces First Patients Enrolled in Phase 3 LEVO-CTS Clinical Trial of Levosimendan
09/19/14 8:30 am EDT
Tenax Therapeutics to Provide Corporate Update and Discuss First Quarter Fiscal Year 2015 Financial Results on September 24, 2014